Source: Official website of the National Development and Reform CommissionIndustry is the key to economic development and the foundation of a country's establishment. Promoting industrial structure adjustment is an important measure to build a modern industrial system, enhance core competitiveneRead All »
According to data from the World Health Organization, 250000 to 500000 people worldwide suffer from spinal cord injuries each year due to reasons such as trauma, and current treatment methods have limited efficacy.With the continuous development of stem cell therapy, scientists from various countrieRead All »
Stem cells are a type of cells with the potential for multi-directional differentiation, self-renewal, and secretion of various cytokines to participate in the repair of damaged tissues and organs. With the advancement of scientific research, stem cells have been widely used in disease treatment resRead All »
Source: China Government WebsiteSeven departments, including the Ministry of Industry and Information Technology, the Ministry of Education, the Ministry of Science and Technology, the Ministry of Transport, the Ministry of Culture and Tourism, the State owned Assets Supervision and Administration CRead All »
On January 15th, the State Council issued the "Opinions on Developing the Silver Hair Economy and Enhancing the Welfare of the Elderly", which is the first policy document in China specifically focusing on the "Silver Hair Economy". Emphasize the development of the anti-aging indRead All »
Source: Official media/online newsAccording to the latest intervention study on anti-aging drugs published in the Chinese Journal of Geriatrics, the consensus of Chinese geriatric experts (2024)The abstract section:Aging and delaying aging are hot topics in the forefront of life science researRead All »
On February 7, 2024, on the occasion of bidding farewell to the old year and ushering in the new year and celebrating the New Year of the the Year of the Loong, Zhejiang Quansheng Biotechnology Co., Ltd. (referred to as "Quansheng Biotechnology") independently developed a new biological clRead All »
Led by Huashan Hospital affiliated to Fudan University, and jointly participated by many institutions and units, such as Shanghai Jiaotong University School of Medicine, Renji Hospital of Shanghai Jiaotong University School of Medicine, the Ninth People's Hospital affiliated to Shanghai JiaotongRead All »
On December 4, 2023, Professor Gregg L. Semenza, winner of the 2019 Nobel Prize in Physiology or Medicine, a dual academician of the National School of Medicine in the United States, and a professor of genetic medicine at Johns Hopkins University School of Medicine, visited the GMP base of ZhejiangRead All »
Consolidate Heart, Brave Practice, Innovative LevelProfessor Semenza Attends Anji CGT SeminarOn December 3rd, Professor Greg Semenza was invited to attend the "2023 Anji Liangshan International Cell and Gene Therapy (CGT) Industry Innovation Seminar" co organized by Zhejiang QuanshenRead All »
On February 7, 2024, during the Chinese New Year celebration, aCGT officially obtained the clinical trial IND approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), with its Class 1 new drug ‘Umbilical Cord Mesenchymal Stem Cell Injection’ (AccepRead All »
On December 4, 2023, Professor Gregg L. Semenza, 2019 Nobel Laureate in Physiology or Medicine, Double Fellow of the National Academy of Medicine, and Professor of the Department of Genetic Medicine at Johns Hopkins University School of Medicine, visited Asia Cell Therapeutics (Zhejiang) Co.,Read All »
In November 2020, 13 stem cell clinical research projects from 12 clinical research institutions including Guangdong Provincial People's Hospital，were completed and filed in accordance with the "Management Measures for Stem Cell Clinical Research (Trial)" (National Health Science andRead All »
On May 24, 2023, the first phase I/II clinical trial of domestic human umbilical cord mesenchymal stem cells for the treatment of decompensated hepatitis B cirrhosis developed by Asia Cell Therapeutics (Zhejiang) Co., Ltd. (hereinafter referred to as "aCell") was officially launched in ShaRead All »
On December 14, 2022, Asia Cell Therapeutics (Zhejiang) Co., Ltd. (aCell), independently developed a new biological class 1 drug "Human Umbilical Cord Mesenchymal Stem Cell Injection" (NO. CXSL2200457). It has officially obtained the implicit approval of drug clinical trials from the NMPA,Read All »